Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal LSTA1 with CRS-HIPEC for Peritoneal Surface Malignancy
NCT06216561Phase 1Withdrawn
- Sponsor
- University of California, San Diego
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of certepetide in Peritoneal metastases, colorectal cancer (CRC), ovarian cancer and 1 more (2 arms), sponsored by University of California, San Diego. Primary endpoints: Adverse events of interest (AE-I) and Drug concentration in tumor. Planned start Nov 2023; status: withdrawn.
02
Drugs
certepetide
03
Conditions
Peritoneal metastasescolorectal cancer (CRC)ovarian cancerappendiceal cancer
Beyond the preview
Go deeper on NCT06216561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216561.